Rheumatoid arthritisLead program · proof-of-concept research completedDocumented clinical proof-of-concept research; further study plans are not confirmed trial commitments.View program
Science & Pipeline
From cannabinoid mechanisms to clinical investigation.
Raphael’s science platform brings together purified cannabinoid research, receptor biology, cellular signaling and inflammatory-disease investigation. The evidence, limits and historical research context are kept visible on this page.
Science at a glance
A research story that can be understood without a dropdown.
Raphael describes a platform focused on investigating cannabinoid biology in inflammatory-disease contexts. Rheumatoid arthritis is the lead research program; the other areas below are separately labelled as historical, exploratory or presented without asserting current operational status.
Scientific platform
A focused framework for studying cannabinoid biology.
Raphael’s platform is organized around the biological questions it investigates—not broad consumer-cannabis terminology. Defined research inputs move through receptor and signaling questions into inflammatory-disease investigation and, where appropriate, clinical study.
Purified cannabinoids→Receptor biology→Cellular signaling→Inflammatory pathways→Clinical investigation
Mechanism framework
Five connected questions.
This framework is a clear way to describe the scope of scientific investigation. It does not establish clinical efficacy, a mechanism of action for a marketed product or a regulatory conclusion.
01Purified cannabinoids
Research begins with defined cannabinoid compounds and controlled formulation questions.
02Receptor biology
Scientists examine receptors expressed in relevant human cells and tissues.
03Cellular signaling
Immune-cell communication and signaling pathways are investigated in context.
04Inflammatory pathways
Research considers cytokine signaling and chronic inflammatory mechanisms.
05Clinical investigation
Study results are kept tied to design, limitations and original source material.
Pipeline snapshot
A status-led view of the research platform.
Each program is described with the evidence that exists today. The presentation intentionally avoids unsupported clinical phases, regulatory commitments and timelines.
Autoimmune & inflammatory researchResearch platform / historical recordLegacy materials describe CBX, immune-cell communication and chronic-inflammation research; the current page does not imply an active program.View record
Oncology supportive careHistorical / exploratory contextLegacy materials describe supportive-care research context, not anticancer efficacy or a confirmed current partnership.View record
Personalized cannabinoid researchResearch hypothesisLegacy materials describe receptor mapping in biopsies and cells; this is not a prescription or treatment service.View record
Rheumatoid arthritis lead program
Clinical Trial & Results
The source record describes a completed U.S. single-group proof-of-concept study managed by Citruslabs. It is the central clinical-research record in Raphael’s clinical research history; it is not presented as an approved treatment or a substitute for independent clinical interpretation.
Read the dedicated RA evidence page
Open proof-of-concept source reportStudy design
Single-group proof of concept
Source report describes a completed U.S. study managed by Citruslabs under IRB approval.Study population
12 adult patients with high disease activity.
Participant count is reported in the company-hosted study summary; selection criteria require protocol-level review.Use context
0.5 mL daily
Each participant used the formula daily at home, according to the source report.Timing
Week 4
Company materials report improvements evident by Week 4.Source-reported outcomes
What the available study summary reports.
Values below are attributed to company-hosted source material. They should not be read as independently replicated findings, a regulatory conclusion or evidence of an established treatment effect.
Company-reported observations
The following statements reproduce the company’s study-summary wording. They describe preliminary observations in 12 participants, not independently confirmed treatment effects or established commercial-product equivalence.
Raphael’s formula improved DAS28 scores from high disease activity to moderate disease severity by Week 4.
12 adult patients with high disease activity.
91.6% of the participants in the clinical trial stated that they would recommend RaphaWell to other RA patients.
The Disease Activity Score (DAS28)—a comprehensive metric assessing RA disease activity—declined by 19.2%, reflecting a shift in participants from high to moderate disease activity.
By Week 4, Raphael’s formula significantly improved:
- Pain levels.
- The ability to live life to the fullest.
- The ability to pursue passions and hobbies.
- The ability to enjoy relationships.
- The ability to enjoy daily life.
- Sleep rating.
- Relaxation rating.
- DAS28 score.
DAS28
19.2% declineThe source reports movement from high to moderate disease activity, with category changes shown in the linked report.Pain & stiffness
Reported symptom measuresNegative pain outcomes are reported from 75% at baseline to 50%; morning stiffness from 75% to 41.67%.Week 4 context
Daily-life, sleep & relaxation measuresScience Data Updates lists pain, daily-life function, sleep, relaxation and DAS28 among measures reported at Week 4.Biomarkers
No statistically significant change reportedThe available report says blood-biomarker analysis did not reveal statistically significant changes.Autoimmune & inflammatory research
Immune-cell communication and inflammatory pathways in the legacy research record.
Legacy Raphael materials describe research around a specific strain labelled CBX, including immune-cell communication, cytokine signaling and chronic-lung-inflammation context in human and mouse-model studies. This record is retained as historical research context; it does not state that the program is active today or that the findings establish a therapy.
Oncology supportive-care research
Historical research context, carefully separated from anticancer claims.
Legacy materials describe exploratory cannabinoid research related to supportive-care effects associated with cancer treatment, including quality-of-life and symptom context. They do not establish anticancer efficacy, an approved use or an active institutional program.
Schneider history
Young-patient supportive-care context
Legacy content refers to work with Schneider Children’s Medical Center of Israel around exploratory supportive-care questions. This historical context does not imply a current institutional partnership.
Review legacy research sourceRambam history
Adult oncology-supportive context
Legacy content also refers to investigation at Rambam oncology and hematology departments. The new site does not describe this as a current partnership or as evidence of anticancer activity.
Review legacy research sourceClinical boundary
Supportive care is not cancer treatment
Research and commercial language stays separate from patient care. No treatment, clinical-trial status or clinical-benefit claim is added beyond the cited historical source record.
Contact the partnerships teamPersonalized cannabinoid research
A receptor-mapping hypothesis—not a personalized-treatment offering.
Legacy materials describe identifying cannabinoid receptors in human biopsies and cells to examine biological variability. This is presented as a research hypothesis and mechanism-oriented direction; Raphael is not represented as providing personalized prescriptions or clinical treatment through this page.
Research question
How do cannabinoid receptors expressed in cells and biopsies vary across biological contexts?
Interpretive boundary
Receptor identification alone does not establish individual response, clinical efficacy, dose selection or a personalized prescription service.
Research & collaboration
Institutional history shown with status boundaries.
Historical collaboration is described separately from a continuing partnership. Institutional history is presented without implying a current partnership or endorsement.
Historical cannabinoid-research context
Legacy materials describe research with the Medical Cannabis Research and Innovation Center at Rambam, including molecular and biochemical cannabinoid research. A later company source references a sponsored research agreement signed in 2019; current scope, exclusivity and status are not asserted here.
Review legacy R&D recordHistorical supportive-care research context
Legacy materials describe an exploratory supportive-care research relationship. It does not establish a current partnership or a treatment claim.
Review legacy R&D recordSource, scope, status
Research relationships are described with source, scope and status boundaries.
Explore collaboration contactEvidence & publications
Publications and source records.
Explore Raphael’s publications and research sources, with direct links to the original records.
Clinical study: source reports & media coverage
Rheumatoid arthritis proof-of-concept results
Company-hosted report describing the Citruslabs-managed single-group study, design context and reported outcomes.
Source report; not a peer-reviewed publication.
Science Data Updates
Raphael’s legacy update lists Week 4 pain, daily-life, sleep, relaxation and DAS28 measures, with its own source context.
Company-posted update.
Citruslabs announcement
Raphael’s Science Data Updates lists a separate Citruslabs announcement. The original social post and its metadata require direct verification; it is not independent clinical evidence.
Open the company source listing; original announcement verification pending.
Stock Titan coverage of the proof-of-concept announcement
External coverage repeats company-reported study facts. It is retained as a linked media record, not independent clinical validation.
External coverage; source reporting remains the underlying company disclosure.
Other scientific publications & research records
The Immunopathology of COVID-19 and the Cannabis Paradigm
Scholarly review of immunopathology and cannabinoid research. It does not establish clinical efficacy for RaphaWell.
DOI: 10.3389/fimmu.2021.631233. Original company-hosted PDF ↗
High-CBD Extract (CBD-X) in Asthma Management: Reducing Th2-Driven Cytokine Secretion and Neutrophil/Eosinophil Activity
Research on CBD-X and inflammatory mechanisms in asthma. This preparation and research context are distinct from the commercial RaphaWell product.
DOI: 10.3390/ph17101382. Original company-hosted PDF ↗
High-CBD Extract (CBD-X) Downregulates Cytokine Storm Systemically and Locally in Inflamed Lungs
Frontiers in Immunology, Volume 13. The legacy site connects this publication to Raphael’s chronic-inflammation research history.
DOI: 10.3389/fimmu.2022.875546.
High CBD extract (CBD-X) modulates inflammation and immune cell activity in rheumatoid arthritis
Miran Aswad, Antonina Pechkovsky, Narmeen Ghanayiem, Haya Hamza and Igal Louria-Hayon. Frontiers in Immunology, 16:1599109. Ex-vivo immune-cell experiments and mouse arthritis models; separate from the 12-person proof-of-concept study.
DOI: 10.3389/fimmu.2025.1599109. Original company-hosted PDF
Acute Effects of Cannabigerol on Anxiety, Stress, and Mood: A Double-Blind, Placebo-Controlled, Crossover, Field Trial
Independent study in healthy adults, separate from Raphael’s rheumatoid-arthritis research and the commercial RaphaWell product.
DOI: 10.1038/s41598-024-66879-0. Read the original methods and limitations. Original company-hosted PDF
Effect of Cannabigerol on Sleep and Quality of Life in Veterans: A Decentralized, Randomized, Placebo-Controlled Trial
A randomized, placebo-controlled research report involving veterans. This version is a preprint and has not been peer reviewed; it is not evidence about the commercial RaphaWell product.
DOI: 10.1101/2023.08.31.23294611. Read the original methods and limitations. Original company-hosted PDF
Hepatotoxicity Evaluation of Cannabidiol, Cannabinol, Cannabichromene and Cannabigerol Using a Human Quad Culture Liver Chip
Research using a human liver-chip model. Laboratory observations do not establish clinical safety or efficacy for RaphaWell.
DOI: 10.1038/s41598-025-12846-2. Read the original methods and limitations. Original company-hosted PDF
A Clinical Study to Assess the Efficacy of Cannabinoid Based Formula in Patients with Active Rheumatoid Arthritis
Citruslabs Research Team report, sponsored by Raphael Pharmaceutical. The 14-page report describes 12 adults in a single-group, eight-week study; no control group is identified. No statistically significant blood-biomarker changes were reported.
Company-sponsored research report, not a peer-reviewed publication.
Cannabigerol (CBG) Modulates Neutrophil Activity and Ameliorates Rheumatoid Arthritis Pathogenesis
Miran Aswad, Antonina Pechkovsky, Haya Hamza and Igal Louria-Hayon. Pharmaceuticals, 19(4):560. Human neutrophil experiments and a mouse arthritis model explore CBG biology; further validation is required before therapeutic positioning.
DOI: 10.3390/ph19040560. This is not the 12-person clinical study. Legacy linked PDF
Patents & intellectual property
A source record—not an issued-patent claim.
The available company-hosted release identifies a reported U.S. provisional application associated with neutrophil-dominant autoimmune diseases, including rheumatoid arthritis. A provisional application is neither presented nor implied to be an issued patent.
Reported provisional record
U.S. Provisional Patent Application No. 63/911,729
The company-hosted release identifies an internal reference, TRMB-RAPH-P-038-USP, and related research context. Legal status, scope, ownership and any subsequent filing require counsel confirmation.
Company-reported indications
Company-provided descriptions of provisional application No. 63/911,729 (internal reference TRMB-RAPH-P-038-USP) include, among other indications:
- Rheumatoid Arthritis (RA)
- Psoriatic Arthritis
- Inflammatory Bowel Diseases (IBD)
- Systemic Lupus Erythematosus (SLE) involving neutrophilic activity
- Gout
These are company-reported indications included in the application description, not independent patent-office or clinical validation. A provisional application is not an issued patent and does not establish a treatment or efficacy claim for RaphaWell. Legal status, scope, ownership and any subsequent filing require counsel confirmation.
Scientific leadership
The scientific record, connected to the centralized leadership page.
These profiles describe the scientific team and documented research relationships. Profiles are presented within the documented scientific record without implying institutional endorsement.
Dr. Igal Louria-Hayon
Legacy material describes scientific leadership connected to cannabinoid research and intercellular communication. His scientific profile is presented without implying institutional endorsement.
Prof. Joseph Press, MD
Legacy material describes a scientific-advisory record and prior pediatric leadership experience. The profile is presented within the documented scientific record.
Dr. Shachar Eduardo
Legacy material describes a scientific-advisory record connected to clinical immunology. The profile is presented within the documented scientific record.
Prof. Alexandra Balbir-Gurman
Legacy material describes a scientific-advisory record connected to rheumatology. The profile is presented within the documented scientific record.